JP2024522237A - ヒトフィブリンまたはフィブリノゲンγＣドメインに結合する抗体および使用方法 - Google Patents

ヒトフィブリンまたはフィブリノゲンγＣドメインに結合する抗体および使用方法 Download PDF

Info

Publication number
JP2024522237A
JP2024522237A JP2023577931A JP2023577931A JP2024522237A JP 2024522237 A JP2024522237 A JP 2024522237A JP 2023577931 A JP2023577931 A JP 2023577931A JP 2023577931 A JP2023577931 A JP 2023577931A JP 2024522237 A JP2024522237 A JP 2024522237A
Authority
JP
Japan
Prior art keywords
seq
antibody
cdr
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577931A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522237A5 (https=
Inventor
ジェフリー スタベンハーゲン
カテリーナ アカスソグルー
Original Assignee
セリーニ バイオ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セリーニ バイオ インコーポレイテッド filed Critical セリーニ バイオ インコーポレイテッド
Publication of JP2024522237A publication Critical patent/JP2024522237A/ja
Publication of JP2024522237A5 publication Critical patent/JP2024522237A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023577931A 2021-06-18 2022-06-20 ヒトフィブリンまたはフィブリノゲンγＣドメインに結合する抗体および使用方法 Pending JP2024522237A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163212409P 2021-06-18 2021-06-18
US63/212,409 2021-06-18
PCT/US2022/034188 WO2022266539A2 (en) 2021-06-18 2022-06-20 ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE

Publications (2)

Publication Number Publication Date
JP2024522237A true JP2024522237A (ja) 2024-06-11
JP2024522237A5 JP2024522237A5 (https=) 2025-06-27

Family

ID=84526539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577931A Pending JP2024522237A (ja) 2021-06-18 2022-06-20 ヒトフィブリンまたはフィブリノゲンγＣドメインに結合する抗体および使用方法

Country Status (6)

Country Link
US (1) US20240279357A1 (https=)
EP (1) EP4355772A4 (https=)
JP (1) JP2024522237A (https=)
AU (1) AU2022293581A1 (https=)
CA (1) CA3222934A1 (https=)
WO (1) WO2022266539A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506425A (ja) * 2009-10-02 2013-02-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア モノクローナル抗体
JP2018501813A (ja) * 2014-11-05 2018-01-25 アネクソン，インコーポレーテッド ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
JP2019519475A (ja) * 2016-04-18 2019-07-11 ファロン ファーマシューティカルズ オサケ ユキチュア ヒト化抗ｃｌｅｖｅｒ−１抗体およびその使用
WO2020025703A1 (en) * 2018-08-01 2020-02-06 Imcheck Therapeutics Sas Anti-btn3a antibodies and their use in treating cancer or infectious disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005116235A2 (en) * 2004-05-07 2005-12-08 The Regents Of The University Of California Endothelial cell apoptosis induced by fibrinogen gamma chain c-terminal fragment
CA2896058A1 (en) * 2012-12-24 2014-07-03 Abbvie Inc. Prolactin receptor binding proteins and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506425A (ja) * 2009-10-02 2013-02-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア モノクローナル抗体
JP2018501813A (ja) * 2014-11-05 2018-01-25 アネクソン，インコーポレーテッド ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
JP2019519475A (ja) * 2016-04-18 2019-07-11 ファロン ファーマシューティカルズ オサケ ユキチュア ヒト化抗ｃｌｅｖｅｒ−１抗体およびその使用
WO2020025703A1 (en) * 2018-08-01 2020-02-06 Imcheck Therapeutics Sas Anti-btn3a antibodies and their use in treating cancer or infectious disorders

Also Published As

Publication number Publication date
US20240279357A1 (en) 2024-08-22
EP4355772A4 (en) 2025-07-30
CA3222934A1 (en) 2022-12-22
WO2022266539A9 (en) 2023-09-14
AU2022293581A1 (en) 2024-01-25
WO2022266539A3 (en) 2023-01-26
WO2022266539A2 (en) 2022-12-22
EP4355772A2 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
US12358979B2 (en) Antibodies that bind interleukin 13 and methods of use
US12269894B2 (en) Antibodies which bind human fibrin or fibrinogen γC domain and methods of use
US20240279357A1 (en) ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE
WO2024173847A2 (en) Antibodies that bind interleukin 4 receptor alpha and methods of use
KR20260007585A (ko) Ox40l에 결합하는 항체 및 사용 방법
WO2022159776A1 (en) Antibodies which bind human fibrin and methods of use
WO2025265071A1 (en) Antibodies that bind tslp and methods of use
WO2024076993A2 (en) Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use
EP4598573A1 (en) Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use
JP2026514143A (ja) Ｏｘ４０ｌに結合する抗体及びその使用方法
WO2026085202A1 (en) Antibodies that bind tslp and methods of use
EA052830B1 (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕ ДОМЕН γC ФИБРИНА ИЛИ ФИБРИНОГЕНА ЧЕЛОВЕКА, И СПОСОБЫ ПРИМЕНЕНИЯ
HK40130326A (zh) 结合白介素4受体α的抗体和使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260406